Melanotan II comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
The 2011 census stated that a majority of the population were Christians (71.93%); 51.48% of the total population were members of the Protestant Church in Germany, 18.34% were Catholics, 2.11% were members of other Christian denominations, 2.27% were members of other religions. 25.8% have no denomination. Even though there is a high level of official belonging to a Christian denomination, the people – especially in the cities – are highly secular in behaviour. As of 2020, the Protestant Church in Germany was the faith of 41.1% of the population. It is organised in the five Landeskirchen named Evangelical Lutheran State Church in Brunswick (comprising the former Free State of Brunswick), Evangelical Lutheran Church of Hanover (comprising the former Province of Hanover), Evangelical Lutheran Church in Oldenburg (comprising the former Free State of Oldenburg), Evangelical Lutheran Church of Schaumburg-Lippe (comprising the former Free State of Schaumburg-Lippe), and Evangelical Reformed Church (covering all the state). Together, these member churches of the Protestant Church in Germany gather a substantial part of the Protestant population in Germany. The Catholic Church was the faith of 16.3% of the population in 2020. It is organised in the three dioceses of Osnabrück (western part of the state), Münster (comprising the former Free State of Oldenburg) and Hildesheim (northern and eastern part of the state). The Catholic faith is mainly concentrated to the regions of Oldenburger Münsterland, the region of Osnabrück, the region of Hildesheim and in the Western Eichsfeld.
body tissues) If steady state is reached, context-sensitive half-life is equal to elimination half-life Only free drug that is in the plasma is metabolised Metabolism results in the concentration of free drug in the peripheral compartment to decrease Due to passive diffusion, free drug will leave the peripheral compartment (i.e. tissues) and enter the central compartment, replenishing any drug that was metabolised from the plasma If steady state is not reached, context-sensitive half-life is shorter than elimination half-life Only free drug that is in the plasma is metabolised Overall the entire body has less lipophilic drug. The infusion was stopped earlier. Not as much drug was able to enter the peripheral compartment. Because steady state is not reached, the peripheral compartment (i.e. tissues) has less free drug than the central compartment The drug continues to move into the peripheral compartment until equilibrium is reached. Remember the drug moves due to passive diffusion. It moves into the peripheral compartment because it has less free drug Once equilibrium is reached, the only other way the drug is able to leave the plasma is by elimination. This causes the free drug concentration in the central compartment to fall As the plasma concentration falls, the concentration gradient of drug reverses and drug moves from peripheral compartment (i.e. tissues) back into plasma, maintaining the plasma concentration of the drug Remifentanil is relatively context insensitive.
=== Variable volume reactions === In some reactions the reactants and the products have significantly different densities. Consequently, as the reaction proceeds the volume of the reaction changes. This variable volume adds terms to the design equations. Taking this volume change into consideration the volume of the reaction becomes:
Sources: en.wikipedia.org
A 2.45 GHz, 6.5 kW source will heat the brain of a 30 g mouse to 90 °C in about 325 milliseconds; a 915 MHz, 25 kW source will heat the brain of a 300 g rat to the same temperature in a second. Special devices designed or modified for this purpose have to be used; use of kitchen-grade microwave ovens is condemned.
=== KLOC === A computer programming expression, the K-LOC or KLOC, pronounced kay-lok, standing for "kilo-lines of code", i.e., thousand lines of code. The unit was used, especially by IBM managers, to express the amount of work required to develop a piece of software. Given that estimates of 20 lines of functional code per day per programmer were often used, it is apparent that 1 K-LOC could take one programmer as long as 50 working days, or 10 working weeks. This measure is no longer in widespread use because different computer languages require different numbers of lines to achieve the same result (occasionally the measure "assembly equivalent lines of code" is used, with appropriate conversion factors from the language actually used to assembly language). Error rates in programming are also measured in "Errors per K-LOC", which is called the defect density. NASA's SATC is one of the few organizations to claim zero defects in a large (>500K-LOC) project, for the space shuttle software. An alternative measurement was defined by Pegasus Mail author David Harris: the "WaP" is equivalent to 71,500 lines of program code, because that number of lines is the length of one edition of Leo Tolstoy's War and Peace.
However, since each SNP requires a distinct probe, the TaqMan assay is limited by the how close the SNPs can be situated. The scale of the assay can be drastically increased by performing many simultaneous reactions in microtitre plates. Generally, TaqMan is limited to applications that involve interrogating a small number of SNPs since optimal probes and reaction conditions must be designed for each SNP.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.